The implementation of a FIP guidance for COVID-19: insights from a nationwide survey.

BACKGROUND: The International Pharmaceutical Federation (FIP) has established an interim guidance of coronavirus disease 2019 (COVID-19) for pharmacists worldwide. The aim of this study was to identify the implementation of FIP guidance in China and provide applicable strategies for further actions.
METHODS: A nationwide cross-sectional survey on Chinese pharmacists was distributed electronically through groups of WeChat between 9 December 2020 and 18 December 2020. The 29-item questionnaire for the survey was designed based on the FIP guidance and knowledge, attitudes, and practices (KAP) framework.
RESULTS: A total of 237 responses from 237 pharmacists (69.20% females) were received. Most pharmacists (81.86%) participated in work related to COVID-19. Respondents referred to other guidelines or consensus more than they did to FIP guidance. Most participants were qualified for the knowledge-based questions regarding COVID-19 (67.51%), had positive attitudes towards pharmacists' roles and actions (61.18%), and were qualified in the practices of prevention measures, infection risk monitoring, and pharmacists' advice (50.63%). Several factors were revealed as having impact on pharmacists' KAP, such as the relevance of participating in work related to COVID-19, work entailments, and information source.
CONCLUSIONS: The FIP guidance has a certain degree of dissemination and implementation in China, which can be improved through effective actions directed towards impact factors. 2021 Annals of Translational Medicine. All rights reserved.

Introduction

Presently, the coronavirus disease 2019 (COVID-19) pandemic is continuing to present a prominent challenge all over the world, and seriously endangering society (1). During a pandemic, the pharmacy becomes a vital access point for medicines and healthcare advice (2). As healthcare professionals, pharmacists join the medical collaborative team and provide pharmaceutical care. In order to support pharmacists in performing their key roles, the International Pharmaceutical Federation (FIP) established an interim guidance of COVID-19 for pharmacists worldwide (3). The FIP guidance covered disease transmission, incubation period, clinical treatment, preventive measures, cleaning and disinfection management, responsibilities and role of pharmacy etc. in primary care, hospital settings, and medical analysis laboratories.

The dissemination and implementation of medical guidance is a global challenge, resulting in the underutilization of guidelines (4-6). The study by Sousa Pinto et al. (7) described the strategy and measures adopted by FIP in collaboration with international experts to support the effective pharmaceutical service and their important value on health systems throughout the pandemic around the world. And previous studies (8-10) have analyzed the knowledge, attitudes, and practices (KAP) of pharmacists and found their actions are largely affected by their KAP towards COVID-19. However, there is a lack of status analysis of the FIP guidance, and pharmacists’ adherence to the guidance has remained ambiguous.

Thus, we investigated pharmacists’ KAP towards COVID-19 by conducting a nationwide survey, aiming to identify current practices and barriers of FIP guidance, and to provide relevant strategies for further actions.

We presented the following article in accordance with the SURGE reporting checklist (available at https://dx.doi.org/10.21037/atm-21-4157).

Methods

Setting and participants

This nationwide cross-sectional survey on Chinese pharmacists has been registered on the Chinese Clinical Trial Registry (ChiCTR2000035213).

A recruitment notice was posted to groups of WeChat through authors’ accounts (Yi and Song) from 9 December through 11 December 2020, which involved pharmacists come from various provinces and autonomous regions in mainland China, with different job titles and job positions. The notice contained a brief introduction including study background and funding resource, objective, procedures, voluntary nature of participation, declarations of anonymity and confidentiality, and notes for completing the questionnaire, as well as a link to the online questionnaire. To collect data of KAP from a cross section, the 18 December 2020 was set as the deadline for completion (maximum of 10 days). The recruitment notice was send out once and no incentive was provided.

All Chinese mainland pharmacists engaged in pharmacy were considered eligible, including pharmacists in hospital, community clinics, or retail pharmacy, regardless of their position, gender, or region. Two similar questions in the questionnaire were set as logic check items, which were used to assess the quality of collected questionnaires. The exclusion criteria were as follows: duplicate answer sheets from the same person; answer sheets where there were contradictory answers; partial completed questionnaires.

Study instrument and measures

The questionnaire was designed based on the FIP guidance (3) and KAP framework (11). The draft questionnaire was initiated by 3 authors (Rong-Sheng Zhao, Zhan-Miao Yi, and Zai-Wei Song) who have been actively participating in the development of FIP guidance (3) and its Chinese version (12). Senior pharmacy experts and epidemiology experts were consulted, and the questionnaire was pre-filled by students and pharmacists who did not then participate in this study. The final survey questionnaire was assessed and modified based on expert suggestions and the results of the pre-surveys.

The questionnaire consisted of 4 parts: demographics (including COVID-19 related information), knowledge, attitudes, and practices. Demographic variables included province/region, gender, job title, education, job responsibilities, working years, job position, participation in COVID-19 work or not, COVID-19 working content, and COVID-19 information source.

The KAP questions in the questionnaire were developed based on the FIP guidance. The knowledge questionnaire had 11 questions with multiple choice and true/false options: 6 (K1-K6) regarding transmission routes, and 5 (K7-K11) regarding clinical treatment of COVID-19 (medicine, convalescent plasma treatment, and vaccines). Attitudes towards COVID-19 were measured by 13 questions: 4 (A1-A4) regarding self-confidence in the role of pharmacists, and 9 (A5-A13) regarding the agreement of measures related to “supporting pharmacists and pharmacy teams”. Each question was scored from 1 to 10. The assessment of respondents’ practices was composed of 5 behaviors (P1-P5), including prevention and control measures, infection risk, and pharmacists’ advice.

Statistical analysis

The statistical analyses were performed with SPSS software version 26.0 (IBM Corp., Armonk, NY, USA). Multiple imputation approach was used for missing data. For quantitative data following a normal distribution, we calculated mean with standard deviations (mean ± SD) and used Pearson’s rank correlation test to identify the possible correlation between variables. For non-normally distributed data, we calculated median with interquartile range [median (IQR)] and used Spearman’s rank correlation test to test the correlation among variables. For qualitative data, we calculated frequency and constituent ratio and used the chi-squared test to compare the difference between the groups. The level of knowledge, attitudes, and practices were summarized and classified. A correct rate of answers above 60% was considered “qualified”, while below 60% was considered “unqualified”. A score of attitudes above 9 was considered “positive”, while below 9 was considered “not positive”.

We used a logistic regression model to identify independent factors of KAP. Empirically, each co-variable needs at least 10 participants in logistic regression models, thus at least 90 responses was required for 9 co-variables in the survey. Univariate analysis was performed for all baseline and COVID-19-related characteristics. Variables with statistical significance as well as gender, professional title, the highest education degree, job duties, length of working years, and operating post (determined by reading relevant literature and combining clinical experience) were included in the multivariate logistic regression using the Enter method. The level of statistical significance was set at P<0.05 (2-tailed analysis).

Ethical approval

All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional ethics board of Peking University Third Hospital (No. IRB00006761-M2020299). The online voluntary and anonymous questionnaire secured the confidentiality of the participants, and did not collect any identity-exposing information of the participants.

Results

Basic information

During the study period, 237 responses from 237 pharmacists were received, and all met the inclusion criteria. Among all respondents, 69.20% were females. Pharmacists were from various regions of mainland China, including Northwest (39.66%), North (18.57%), Central (16.46%), Southwest (8.86%), South (7.17%), Northeast (5.91%), and East China (3.38%). Among the included pharmacists, 93.67% held a bachelor’s degree or above, and 78.06% has been working as a pharmacist for more than 5 years.

During the pandemic, 194 pharmacists (81.86%) participated in COVID-19 related work, such as drug supply and guarantee, pharmacy information support, drug dispensation, and guidelines/consensus development. The main information source for COVID-19 was in-hospital training, followed by National Health Commission and other official guidance documents, and other guidelines or consensus. Among the included pharmacists, 48.95% had studied the FIP guidance. Demographics of pharmacists and COVID-19-related information are shown in .

Table 1

Demographics of pharmacists and COVID-19-related information

Characteristics	Subgroup	n	%
Gender	Female	164	69.20
	Male	73	30.80
Job title	Primary and below	62	26.16
	Junior	104	43.88
	Senior	71	29.96
Education background	College and below	15	6.33
	Bachelor	128	54.01
	Master	71	29.96
	Doctor	23	9.70
Job responsibility	Clinical pharmacist	114	48.10
	Drug dispensing	59	24.89
	Pharmacy administrator	47	19.83
	Othersa	17	7.17
Working years	1–5	52	21.94
	6–10	69	29.11
	11–15	48	20.25
	16–20	20	8.44
	≥21	48	20.25
Job position (multiple choice)	General clinic	83	35.02
	General ward	77	32.49
	General emergency	32	13.50
	Fever clinic	19	8.02
	Isolation ward or Fangcang Shelter	8	3.38
	Othersb	104	43.88
COVID-19 work	Participation	194	81.86
	No participation	43	18.14
Working content of COVID-19 (multiple choice)	Drug supply and guarantee	94	39.66
	Pharmacy information support	87	36.71
	Drug dispensation	86	36.29
	Drug evaluation	31	13.08
	Disinfectant preparation	23	9.70
	Guidelines/consensus development	14	5.91
	Othersc	69	29.11
Information source of COVID-19 (multiple choice)	In-hospital training	208	87.76
	National Health Commission and other official guidance documents	194	81.86
	Other guidelines/consensus	165	69.62
	News media	145	61.18
	FIP guidance	116	48.95
	Journal articles	107	45.15
	Academic conferences	90	37.97
	Othersd	17	7.17

a, laboratory pharmacist (TDM and genetic testing), prescription reviews, drug information pharmacist, etc.; b, other departments of drug supply and guarantee, pharmacy laboratory (TDM and genetic testing), clinical trial institution, quality control, etc.; c, pharmacy consultation, popular science writing, conducting related research, laboratory nucleic acid testing, infection control work, etc.; d, municipal continuation education projects, clinical management of COVID-19 patients, etc.; COVID-19, coronavirus disease 2019; TDM, therapeutic drug monitoring; FIP, International Pharmaceutical Federation.

Knowledge: transmission routes and clinical treatment

The knowledge questionnaire consisted of 2 parts with 11 questions (K1-K11): transmission routes and clinical treatment of COVID-19 (answers are shown in ). Overall, the number of correct answers was 7 [2] {median [IQR]}, and 67.51% of respondents were classified as qualified. In terms of transmission routes (K1-K6), most pharmacists answered correctly; however, the correct answer rate of K3 on pregnant or lactating patients with COVID-19 was only 11.81%. The correct rate of the application of convalescent plasma therapy (K9) was 23.63%. The working content of COVID-19 “drug dispensation” (negative correlation) and the information source of COVID-19 “other guidelines or consensus” (positive correlation) were statistically significant independent factors in both univariate and multivariate logistic regression analysis ().

Figure 1

Results of knowledge. K1—which statement about the transmission of the virus is correct: (correct) the most common way of transmission is close contact between people; (correct) human-to-human transmission occurs mainly through droplets produced when the infected person speaks, coughs or sneezes; (correct) droplets from patients infected with COVID-19 may fall on the mouth, nose, and eyes of people around, or be inhaled into the lungs; (correct) COVID-19 can be transmitted by touching the surface or object on which the virus is attached, and then touching your mouth, nose, or eyes. K2—(correct) the virus can be transmitted by infected patients with or without symptoms, is it correct? K3—which of the following statements about people during pregnancy and lactation is correct: (correct) for pregnant women, the mother-to-child transmission of the virus during pregnancy and perinatal period is still unclear; (correct) no virus has been detected in breast milk of breastfeeding women infected with COVID-19; (correct) mothers with COVID-19 can breastfeed; none of the above is correct. K4—which statement about COVID-19 patients is correct: (correct) COVID-19 patients may still be infectious for 2 weeks after their symptoms resolve; COVID-19 patients are unlikely to be infected again within a short period of time after recovery; (correct) most infected people with symptoms will develop symptoms within 14 days of exposure; none of the above is correct. K5—if you have recently been in contact with a confirmed or suspected COVID-19 case and/or have a recent travel history to affected areas, at least how long is it recommended to implement strict quarantine: 7 days; 10 days; (correct) 14 days; 21 days. K6—which statement about respiratory droplets and contact transmission is correct: the virus can only be transmitted through respiratory droplets; the virus can only be transmitted through contact; (correct) respiratory droplets and contact can transmit the virus; none of the above is correct. K7—which of the following statements about COVID-19 clinical treatment is correct? There are currently specific therapeutic drugs for COVID-19; (correct) at present, antiviral therapy is mainly used, and symptomatic and supportive treatment is carried out according to the patient’s clinical situation; glucocorticoids can be routinely used to treat COVID-19; None of the above is correct. K8—(correct) COVID-19 patients taking ACEI or ARB drugs should continue to take the drug, is it correct? K9—which of the following statements about convalescent plasma therapy (CPT) are correct: (correct) convalescent plasma therapy has been successfully used in the treatment of atypical pneumonia (SARS); (correct) convalescent plasma therapy has been successfully used for the treatment of influenza A H1N1; (correct) for COVID-19 patients whose disease is progressing rapidly, severely or critically, convalescent plasma therapy can be tried; none of the above is correct. K10—(false) anti-pneumonia vaccines (such as Streptococcus pneumoniae vaccine or Haemophilus influenzae type B vaccine) can prevent COVID-19, is it correct? K11—(correct) glucocorticoids are not recommended for routine use in viral pneumonia or acute respiratory distress syndrome, is it correct? COVID-19, coronavirus disease 2019; SARS, severe acute respiratory syndrome.

Table 2

Logistic regression for being qualified in knowledge

Characteristics	Subgroup	Univariate analysis			Multivariate analysis
		OR (95% CI)	P value		OR (95% CI)	P value
Gender	Male (vs. female)	1.067 (0.591–1.928)	0.829		1.028 (0.536–1.970)	0.935
Job title	Primary and below	0.948 (0.487–1.847)	0.876		1.461 (0.580–3.677)	0.421
	Junior	Reference			Reference
	Senior	1.082 (0.565–2.070)	0.812		0.606 (0.230–1.596)	0.311
Education background	College and below	0.443 (0.151–1.302)	0.139		0.478 (0.117–1.951)	0.304
	Bachelor	Reference			Reference
	Master	1.056 (0.569–1.958)	0.863		1.090 (0.509–2.335)	0.825
	Doctor	3.373 (0.949–11.982)	0.060		3.834 (0.873–16.843)	0.075
Job responsibility	Clinical pharmacist	Reference			Reference
	Drug dispensing	0.495 (0.257–0.955)	0.036		0.569 (0.221–1.464)	0.242
	Pharmacy administrator	0.920 (0.436–1.941)	0.826		1.309 (0.508–3.372)	0.577
	Others	0.937 (0.305–2.872)	0.909		1.190 (0.348–4.064)	0.781
Working years	1–5	0.565 (0.260–1.226)	0.148		0.430 (0.175–1.060)	0.067
	6–10	Reference			Reference
	11–15	0.857 (0.377–1.951)	0.713		0.797 (0.315–2.016)	0.632
	16–20	0.655 (0.226–1.900)	0.437		1.201 (0.318–4.542)	0.787
	≥21	0.588 (0.266–1.301)	0.190		0.925 (0.267–3.210)	0.903
Job position (multiple choice)	General clinic (vs. no)	0.658 (0.375–1.154)	0.144		1.001 (0.411–2.441)	0.998
	General ward (vs. no)	1.196 (0.664–2.153)	0.551		1.111 (0.486–2.543)	0.803
	General emergency (vs. no)	1.268 (0.557–2.891)	0.571		1.841 (0.605–5.599)	0.282
	Fever clinic (vs. no)	1.381 (0.479–3.983)	0.551		1.523 (0.409–5.676)	0.531
	Isolation ward or Fangcang Shelter (vs. no)	3.477 (0.420–28.774)	0.248		2.848 (0.273–29.711)	0.382
	Others (vs. no)	1.151 (0.664–1.994)	0.617		0.762 (0.294–1.974)	0.575
COVID-19 work	Participation (vs. no)	1.004 (0.496–2.032)	0.992
Working content of COVID-19 (multiple choice)	Drug supply and guarantee (vs. no)	0.890 (0.511–1.548)	0.679
	Pharmacy information support (vs. no)	1.209 (0.684–2.137)	0.515
	Drug dispensation (vs. no)	0.477 (0.273–0.835)	0.010		0.400 (0.203–0.790)	0.008
	Drug evaluation (vs. no)	1.765 (0.725–4.297)	0.211
	Disinfectant preparation (vs. no)	0.725 (0.299–1.756)	0.476
	Guidelines/consensus development (vs. no)	3.041 (0.663–13.937)	3.041
	Others (vs. no)	0.864 (0.478–1.563)	0.629
Information source of COVID-19 (multiple choice)	In-hospital training (vs. no)	0.926 (0.401–2.143)	0.858
	National Health Commission and other official guidance documents (vs. no)	1.647 (0.836–3.248)	0.149
	Other guidelines/consensus (vs. no)	1.956 (1.098–3.484)	0.023		1.905 (0.999–3.631)	0.050
	News media (vs. no)	0.857 (0.489–1.503)	0.591
	FIP guidance (vs. no)	1.330 (0.770–2.296)	0.307
	Journal articles (vs. no)	1.061 (0.614–1.834)	0.831
	Academic conferences (vs. no)	0.800 (0.459–1.395)	0.431
	Others (vs. no)	0.874 (0.311–2.457)	0.798

COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval.

Attitudes: pharmacists’ roles and actions

Overall, 145 pharmacists (61.18%) were classified as having positive attitudes. The score of pharmacists’ roles and actions was 9.2 [1.4] {median [IQR]}. The scores of the attitudes section are shown in . When asked to grade their self-confidence in the role of pharmacists (A1-A4), 129 participants (54.43%) displayed positive attitudes. Compared with pharmacists’ role in clinical management of COVID-19 {median [IQR]: 9 [2]}, pharmacists were more confident about their role in relevant research {median [IQR]: 10 [2]}. As for the agreement of measures related to “supporting pharmacists and pharmacy teams” (A5-A13), the median (IQR) was 9.4 (1.4). Among items A5-A13, the item “Recognize pharmacists as pivotal anti-epidemic staff” (A5) returned the lowest score of 8.0 (3.0). The COVID-19 information source “the National Health Commission and other official guidance documents” was identified as a significant positive impact factor in both univariate and multivariate logistic regression analysis ().

Figure 2

Results of attitudes. Please score the degree of self-confidence for the following pharmacists’ roles: A1—pharmacists should actively participate in the diagnosis and treatment of COVID-19; A2—pharmacists should actively participate in COVID-19 research; A3—pharmacists can play a role in the diagnosis and treatment of COVID-19; A4—pharmacists can play a role in COVID-19 research. Please score the agreement of the following measures of “supporting pharmacists and pharmacy teams”: A5—recognize pharmacists as pivotal anti-epidemic staff; A6—widely speak out to encourage the deployment of pharmacists to the frontline of the epidemic; A7—encourage to give full play of the expertise of pharmaceutical scientists and pharmacists, participate in vaccine and drug research and development, and provide evidence-based treatment information; A8—encourage all pharmacy-related practitioners to unite and cope with the global pandemic of COVID-19; A9—encourage pharmacists to continue to provide pharmaceutical services, and allow remote pharmaceutical services when necessary (such as remote pharmaceutical consultation, home delivery of medicines, etc.); A10—ensure that the pharmacist can obtain the necessary prevention and control equipment; A11—provide pharmacists with the latest, most accurate, and comprehensive clinical information related to COVID-19; A12—carry out continuing education related to infectious diseases and emergency response to ensure that pharmacists have a timely grasp of the latest clinical and policy information; A13—provide pharmacists with necessary support, including logistics, funding, viral nucleic acid testing, mental health guidance, etc. COVID-19, coronavirus disease 2019.

Table 3

Logistic regression for being positive in attitudes

Characteristics	Subgroup	Univariate analysis			Multivariate analysis
		OR (95% CI)	P value		OR (95% CI)	P value
Gender	Male (vs. female)	1.353 (0.772–2.371)	0.291		1.240 (0.680–2.259)	0.483
Job title	Primary and below	1.345 (0.706–2.562)	0.368		1.463 (0.628–3.407)	0.378
	Junior	Reference			Reference
	Senior	1.655 (0.882–3.108)	0.117		1.486 (0.610–3.620)	0.383
Education background	College and below	0.686 (0.234–2.010)	0.492		0.951 (0.239–3.779)	0.943
	Bachelor	Reference			Reference
	Master	0.869 (0.480–1.573)	0.643		1.012 (0.497–2.063)	0.973
	Doctor	1.125 (0.444–2.850)	0.804		1.269 (0.415–3.883)	0.676
Job responsibility	Clinical pharmacist	Reference			Reference
	Drug dispensing	1.531 (0.791–2.964)	0.206		1.823 (0.733–4.530)	0.196
	Pharmacy administrator	1.409 (0.694–2.862)	0.343		1.222 (0.523–2.855)	0.643
	Others	0.646 (0.233–1.797)	0.403		0.748 (0.248–2.250)	0.605
Working years	1–5	1.008 (0.484–2.099)	0.983		1.012 (0.442–2.318)	0.978
	6–10	Reference			Reference
	11–15	1.042 (0.491–2.211)	0.914		1.025 (0.448–2.347)	0.953
	16–20	1.024 (0.371–2.828)	0.963		0.956 (0.280–3.267)	0.943
	≥21	1.366 (0.633–2.946)	0.427		1.084 (0.346–3.4030	0.890
Job position (multiple choice)	General clinic (vs. no)	1.289 (0.741–2.243)	0.369		1.397 (0.603–3.237)	0.435
	General ward (vs. no)	1.267 (0.721–2.228)	0.411		1.819 (0.798–4.146)	0.154
	General emergency (vs. no)	1.467 (0.660–3.258)	0.347		0.788 (0.265–2.345)	0.669
	Fever clinic (vs. no)	1.412 (0.517–3.855)	0.501		1.736 (0.486–6.204)	0.396
	Isolation ward or Fangcang Shelter (vs. no)	1.060 (0.247–4.543)	0.938		1.166 (0.235–5.771)	0.851
	Others (vs. no)	0.956 (0.565–1.617)	0.866		1.756 (0.685–4.502)	0.241
COVID-19 work	Participation (vs. no)	1.037 (0.528–2.040)	0.915
Working content of COVID-19 (multiple choice)	Drug supply and guarantee (vs. no)	1.298 (0.758–2.225)	0.342
	Pharmacy information support (vs. no)	1.146 (0.665–1.975)	0.624
	Drug dispensation (vs. no)	1.030 (0.598–1.774)	0.915
	Drug evaluation (vs. no)	0.861 (0.400–1.854)	0.703
	Disinfectant preparation (vs. no)	1.212 (0.299–1.756)	0.676
	Guidelines/consensus development (vs. no)	1.151 (0.374–3.550)	0.806
	Others (vs. no)	1.275 (0.711–2.285)	0.414
Information source of COVID-19 (multiple choice)	In-hospital training (vs. no)	0.809 (0.358–1.826)	0.610
	National Health Commission and other official guidance documents (vs. no)	2.341 (1.197–4.575)	0.013		2.385 (1.114–5.107)	0.025
	Other guidelines/consensus (vs. no)	1.400 (0.797–2.458)	0.241
	News media (vs. no)	0.815 (0.475–1.399)	0.458
	FIP guidance (vs. no)	1.539 (0.909–2.606)	0.109
	Journal articles (vs. no)	1.290 (0.651–2.187)	0.344
	Academic conferences (vs. no)	1.073 (0.626–1.841)	0.431
	Others (vs. no)	1.177 (0.420–3.299)	0.757

COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval.

Practices: prevention, control measures, and pharmacist’s advice

The assessment of practices was composed of 5 behaviors (P1-P5). Answers to the knowledge section are shown in . The number of correct answers was 3 [1] {median [IQR]}, and 50.63% of pharmacists were classified as qualified. The incorrect answers were mainly focused on disinfectant. Among them, 78.90% (P2) and 60.76% pharmacists (P4) believed that chlorhexidine could effectively inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Additionally, 23.21% pharmacists held that 75% ethanol could be used to disinfect large areas such as the air. The job position “others” (positive correlation), participation in COVID-19 work (positive correlation), and the COVID-19 information source “others” (negative correlation) were statistically significant independent factors in both univariate and multivariate logistic regression analysis ().

Figure 3

Results of practices. P1—which statement about personal prevention is correct: (correct) keep short or tied hair, avoid growing beards, avoid wearing jewelry, watches, and makeup; (correct) wear a mask at work to prevent self-infection and further transmission; (correct) wear gloves, masks, protective masks, or goggles, and protective clothing when necessary during work; no need to wear a respirator when participating in operations that may generate aerosols. P2—which statement about cleaning and disinfection is correct: (correct) frequent hand hygiene and facial cleansing; (correct) disinfect the surface of any objects that patients or the public may touch; UV radiation, heat, 75% ethanol, chlorine-containing disinfectant, and chlorhexidine are all suitable for disinfection; 75% ethanol can be used to disinfect large areas such as air. P3—which of the following statement is correct: (correct) keep a distance of 1 to 2 meters from the patient and the public; close contact with others such as hugging and shaking hands will not increase the risk of infection; (correct) when coughing or sneezing, cover the mouth and nose with a clean tissue or the elbows; none of the above is correct. P4—which of the following disinfectants can effectively kill the virus: chlorhexidine; (correct) chlorine dioxide; (correct) disinfectant whose active ingredient is iodine (0.5%); (correct) hydrogen peroxide disinfectant; (correct) ethylene oxide; (correct) alcohol-based quick-drying hand sanitizer; others. P5—which of the following statements about COVID-19 infection risk monitoring and pharmacist recommendations for patients is correct: (correct) the pharmacist should monitor the patient’s infection risk based on the patient’s clinical symptoms (such as cough, fever, or dyspnea) and epidemiological history (contact with confirmed or suspected cases and/or travel history to affected areas), and provide targeted intervention measures; (correct) for patients with clinical symptoms and without recent epidemiological history, pharmacists should recommend strict home isolation for at least 14 days; (correct) for patients who have not clinical symptoms and conform to the epidemiological history, pharmacists should recommend strict home isolation for at least 14 days. If symptoms occur during the isolation period, they should seek medical attention in time; (correct) for patients who have clinical symptoms and conform to the epidemiological history, pharmacists should advice proper prevention and timely medical treatment for testing and follow-up diagnosis and treatment.

Table 4

Logistic regression for being qualified in practices

Characteristics	Subgroup	Univariate analysis			Multivariate analysis
		OR (95% CI)	P value		OR (95% CI)	P value
Gender	Male (vs. female)	1.168 (0.673–2.029)	0.581		1.057 (0.566–1.974)	0.861
Job title	Primary and below	0.846 (0.450–1.587)	0.602		0.974 (0.407–2.329)	0.952
	Junior	Reference			Reference
	Senior	1.108 (0.605–2.028)	0.739		1.036 (0.396–2.707)	0.943
Education background	College and below	0.266 (0.072–0.988)	0.048		0.718 (0.143–3.599)	0.687
	Bachelor	Reference			Reference
	Master	1.374 (0.767–2.461)	0.286		1.205 (0.585–2.483)	0.613
	Doctor	1.996 (0.791–5.036)	0.143		1.660 (0.520–5.293)	0.392
Job responsibility	Clinical pharmacist	Reference			Reference
	Drug dispensing	0.536 (0.283–1.014)	0.055		1.173 (0.462–2.978)	0.737
	Pharmacy administrator	0.815 (0.413–1.611)	0.557		0.788 (0.327–1.899)	0.595
	Others	0.694 (0.250–1.929)	0.484		0.925 (0.279–3.072)	0.899
Working years	1–5	1.133 (0.551–2.331)	0.734		1.332 (0.570–3.111)	0.508
	6–10	Reference			Reference
	11–15	1.249 (0.596–2.618)	0.556		1.254 (0.535–2.938)	0.603
	16–20	0.971 (0.359–2.629)	0.954		1.156 (0.322–4.149)	0.824
	≥21	0.694 (0.330–1.459)	0.335		0.693 (0.209–2.304)	0.550
Job position (multiple choice)	General clinic (vs. no)	0.688 (0.402–1.176)	0.172		1.371 (0.596–3.154)	0.458
	General ward (vs. no)	0.735 (0.426–1.269)	0.269		1.421 (0.638–3.167)	0.390
	General emergency (vs. no)	0.840 (0.398–1.773)	0.648		0.724 (0.245–2.141)	0.560
	Fever clinic (vs. no)	1.091 (0.427–2.790)	0.856		2.205 (0.639–7.610)	0.211
	Isolation ward or Fangcang Shelter (vs. no)	1.652 (0.386–7.076)	0.499		1.841 (0.362–9.363)	0.462
	Others (vs. no)	2.364 (1.397–4.000)	0.001		4.172 (1.637–10.635)	0.003
COVID-19 work	Participation (vs. no)	2.202 (1.107–4.381)	0.024		2.194 (1.008–4.776)	0.048
Working content of COVID-19 (multiple choice)	Drug supply and guarantee (vs. no)	1.185 (0.704–1.996)	0.523
	Pharmacy information support (vs. no)	0.996 (0.587–1.690)	0.989
	Drug dispensation (vs. no)	1.288 (0.757–2.190)	0.351
	Drug evaluation (vs. no)	1.412 (0.658–3.030)	0.376
	Disinfectant preparation (vs. no)	1.300 (0.546–3.093)	0.553
	Guidelines/consensus development (vs. no)	0.369 (0.112–1.212)	0.100
	Others (vs. no)	1.286 (0.732–2.257)	0.381
Information source of COVID-19 (multiple choice)	In-hospital training (vs. no)	1.530 (0.696–3.363)	0.290
	National Health Commission and other official guidance documents (vs. no)	0.776 (0.399–1.507)	0.453
	Other guidelines/consensus (vs. no)	2.153 (1.220–3.798)	0.008		1.633 (0.861–3.098)	0.133
	News media (vs. no)	0.971 (0.576–1.637)	0.911
	FIP guidance (vs. no)	1.247 (0.749–2.077)	0.396
	Journal articles (vs. no)	1.390 (0.832–2.324)	0.209
	Academic conferences (vs. no)	1.841 (1.081–3.135)	0.025		1.700 (0.943–3.065)	0.078
	Others (vs. no)	0.276 (0.087–0.873)	0.028		0.251 (0.065–0.970)	0.045

COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval.

Correlation between knowledge, attitudes, and practices

The chi-squared (χ2) test was performed to evaluate the correlation between knowledge and attitudes (K&A), knowledge and practices (K&P), and attitudes and practices (A&P). No significant correlation was observed in any of these pairings (K&A: χ2=1.368, P=0.242; K&P: χ2=0.312, P=0.577; A&P: χ2=1.492, P=0.222).

Discussion

Currently, the important role of pharmacist and innovative strategies of pharmacy interventions have been widely established and published. However, the information on the dissemination and implementation of guidance for pharmacists is limited and remains to be fully understood. In this study, we assessed the implementation of FIP guidance through a survey of the knowledge, attitudes, and practices of representative pharmacists. Most pharmacists were shown to have sufficient knowledge of transmission routes and clinical treatment for COVID-19, as well as positive attitudes towards their roles and actions. About half of the cohort were qualified in the practices of prevention and control measures, risk factor control, and pharmacist’s advice. Several factors were revealed as having impact on pharmacists’ KAP, such as whether they were participating in COVID-19 work, working content, and information source.

Most respondents (67.51%) showed appropriate knowledge regarding transmission routes and clinical treatment, which is consistent with studies in other countries, such as Lebanon, Turkey, Vietnam, and Pakistan (9,13-15). Over 60% had positive attitudes towards pharmacists’ roles and actions. However, pharmacists referred to other guidelines or consensus more than FIP guidance, including information and guidance from the Chinese National Health Commission (16) and those developed by Chinese associations and institutions (17,18). Authorized guidance of COVID-19 was a positive impact factor to the attitudes of pharmacist towards COVID-19.

The accessibility, validity, adaptability, applicability, and usability were considered important factors to guidance implementation (6,19,20). Mandatory requirements and supervision by authorities also played an essential role. During the COVID-19 pandemic, it was required that all medical staff should learn the authorized guidance of COVID-19. Thus, pharmacists obtaining COVID-19 information from official guidance documents may have better knowledge and attitudes.

Effective prevention measures and infection risk monitoring for pharmacists are necessities during the COVID-19 pandemic, which can reduce the risk of infection for both themselves and others (21). They must maintain and promote good hygiene conditions, take prevention measures such as wearing disposable gloves, protective clothing, eye protection, and masks, and maintain appropriate social distance with patients and other healthcare staff (15,21,22). In our study, 69.62% of pharmacists took adequate prevention measures against workplace infections. The result is similar to the study in Henan, where 89.7% of healthcare staff took effective measures (23). However, it has been reported that as many as 72.4% of pharmacists in Jordan believed that keeping a distance of half a meter from COVID-19 patients can effectively prevent viral transmission (24). Thus, it is still necessary to seek an understanding of pharmacists’ behavior around the world to determine barriers for the implementation of medical guidance.

As for practice to promote treatment of COVID-19, although some antiviral agents such as interferon-α, ribavirin, arbidol and chloroquine phosphate were observed to have therapeutic effect on COVID-19 based on available clinical studies, there is still no specific therapeutic drug approved for COVID-19 worldwide (25). Thus, pharmacists are encouraged to cooperate with clinicians to closely monitor and evaluate the medication safety and efficacy.

To the best of our knowledge, our study was the first survey to explore the implementation of FIP guidance on COVID-19. The status of pharmacists’ adherence and barriers of FIP guidance were analyzed and identified. However, our study had a few limitations that need to be addressed in further studies. Firstly, the study sample was relatively small and covered only mainland China, and the KAP of pharmacists from other regions should be considered. Secondly, this was a self-reported online survey through WeChat, face-to-face interviews might yield more information towards a better understanding of the implementation of the guidance. Due to unknown number of duplicate people in different WeChat groups, we did not know the number of nonresponse and the response rate was not calculated. Thirdly, bias cannot be excluded due to the nature of convenience sampling; thus, stratified sampling may strengthen sample representativeness.

In addition to strengthening the usability and applicability of such guidelines, it is encouraged to fully involve the knowledge, attitudes, and relevance of target users in the future directives. It is also important to integrate local policy to gain support and promotion from the relevant authorities during guidance implementation (26).

Conclusions

Our study revealed an appropriate level of knowledge, attitudes, and practices towards COVID-19 among pharmacists in mainland China, which indicated that the FIP guidance has a certain degree of dissemination and implementation in China. However, the implementation of guidelines can be improved through effective actions directed towards impact factors.

The article’s supplementary files as